title: Therapeutically reeducating macrophages to treat GBM.
abstract: Glioblastoma multiforme (GBM) is the most common type of aggressive malignant brain cancer. The current lack of successful therapeutics means that this disease has a dismal prognosis. However, a new study in mice offers hope for patients with GBM by demonstrating the efficacy of a novel drug that targets GBM-associated macrophages (pages 1264–1272).
authors.affiliation: 1] Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Graduate Program in Immunology, Harvard Medical School, Boston, Massachusetts, USA.
authors.forename: Christopher
authors.initials: C
authors.lastname: Garris
authors.forename: Mikael J
authors.initials: MJ
authors.lastname: Pittet
mesh_terms: D000818:Animals; D001932:Brain Neoplasms / Q000473:pathology*; D005909:Glioblastoma / Q000473:pathology*; D008264:Macrophages / Q000166:cytology*; D016186:Receptor, Macrophage Colony-Stimulating Factor / Q000037:antagonists & inhibitors*
chemical_list: D016186:Receptor, Macrophage Colony-Stimulating Factor